Regulatory agencies are escalating the pressure on outsourced sterile manufacturing.
Regulatory agencies are escalating the pressure on outsourced sterile manufacturing. Establishing a back-up solution with Patheon is like having an insurance policy for your sterile product supply. Why put your sterile product supply at risk when you can have cost-effective backup manufacturing that’s ready when you need it?
Our newly launched Sterile Backup Supply Program offers:
Accessible – No volume commitment required.
Cost effective – externalizing your supply back-up means no need to carry capital and overhead.
Reliable – Patheon’s best-in-class quality and regulatory track record.
Readily available – Available capacity and ability to maneuver tech transfer quickly and produce within a large existing set of delivery formats.
Be safe. Be sure. Contact Patheon today.
Call +1 866-PATHEON (+1 866-728-4366) or click here to find out more about how Patheon can be your reliable backup for sterile manufacturing.
Patheon – reliable backup for sterile products supported by two state-of-the-art sterile manufacturing facilities.
Ferentino, Italy
Houses four cGMP Lyophilization units with a total production capacity of 990 ft2 (92 m2 ) and is designed for the aseptic filling of small volume parenterals. This site also offers a dedicated sterile suite for large volume parenterals filled in glass bottles.
Monza, Italy
Features three separate sterile areas housing six lyophilization units offering a total of 2,131 ft2 (198 m2) and are ideal for the commercial manufacture of biopharmaceuticals and small molecules. The facility is also designed for the aseptic filling of small volume parenterals.
More information is available at www.patheon.com/Marketing/Sterile_Backup_v2/sterileBackup.html
US Headquarters
Patheon Inc.
4721 Emperor Blvd, Suite 200 | Durham | NC | 27703-8580 USA
P: +1 919 226 3200 | F: +1 919 474 2269
Patheon.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.